子宮頸部異形成市場：診断タイプ、治療タイプ、エンドユーザー別-2025-2030年の世界予測

子宮頸部異形成市場は、2023年に7億5,439万米ドルと評価され、2024年には8億603万米ドルに達すると予測され、CAGR 6.93%で成長し、2030年には12億652万米ドルに達すると予測されています。

ヒトパピローマウイルス（HPV）による子宮頸部細胞の前がん変化を特徴とする子宮頸部異形成は、子宮頸がん予防における役割のため、ヘルスケア市場で大きな注目を集めています。その必要性は、治療しなければ子宮頸がんに進行する可能性があることから生じ、パップスメアやHPV検査のようなスクリーニングプログラムの重要性が強調されています。これらのアプリケーションは、予防接種と並んで予防ヘルスケアのバックボーンを形成しており、病院、診療所、診断センターをエンドユーザーとする市場力学に大きな影響を与えています。子宮頸部異形成市場は、認知度の向上、子宮頸がん検診に対する政府の取り組み、診断技術の進歩によって成長する見込みです。主な成長要因としては、世界のHPV罹患率の上昇、女性の健康重視の高まり、次世代診断検査の開発などが挙げられます。地域的には、アジア太平洋とラテンアメリカの新興市場は、ヘルスケア・インフラの開拓と医療アクセスの向上により、力強い成長ゾーンとなっています。とはいえ、診断にかかる費用の高さ、農村部における認知度の低さ、ワクチン接種へのためらいといった課題が、市場拡大の妨げとなっています。これらを克服するため、企業は費用対効果の高い診断ソリューションと啓発プログラムに注力すべきです。革新的な分野としては、非侵襲的で正確かつ迅速な診断法の開発、予測診断のためのAIと機械学習の活用、HPVを幅広く予防するためのワクチン製剤の改良などが挙げられます。技術交換や地域拡大のためのパートナーシップの締結は、成長を促進する可能性があります。市場は競合関係にあり、大手企業は研究開発や戦略的提携に投資してポートフォリオを強化しています。堅調な事業成長を目指す企業は、最先端の研究を優先し、手頃な価格のヘルスケアソリューションを提供し、手付かずの市場を開拓する一方で、規制状況を乗り切り、認知度の低い地域の社会文化的障壁に対処する必要があります。

市場力学：急速に進化する子宮頸部異形成市場の主要市場インサイトを公開

子宮頸部異形成市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の子宮頸がん罹患率の増加
  • 子宮頸がん検診を強化する政府によるイニシアティブの高まり
  • 患者の低侵襲手術への傾斜
• 市場抑制要因
  • 診断機器および治療費の高騰
• 市場機会
  • 検診機器およびその他の支援機器の技術的進歩
  • 子宮頸部スクリーニングプログラムの登場
• 市場の課題
  • 新興諸国における認識不足と診断機器の承認率の低さ

ポーターの5つの力：子宮頸部異形成市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：子宮頸部異形成市場における外部からの影響の把握

外部マクロ環境要因は、子宮頸部異形成市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析子宮頸部異形成市場における競合情勢の把握

子宮頸部異形成市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス子宮頸部異形成市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、子宮頸部異形成市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨子宮頸部異形成市場における成功への道筋を描く

子宮頸部異形成市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で子宮頸がんの発生率が増加
    • 政府による子宮頸部異形成のスクリーニング強化に向けた取り組みの拡大
    • 低侵襲手術に対する患者の傾向
  • 抑制要因
    • 診断機器と治療のコストが高い
  • 機会
    • 検査装置やその他の支援機器の技術的進歩
    • 子宮頸がん検診プログラムの出現
  • 課題
    • 新興諸国における認知度の低さと診断機器の承認率の低さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 子宮頸部異形成市場診断タイプ別

• 生検
• 膣鏡検査
• HPV検査
• パップスメア検査

第7章 子宮頸部異形成市場治療の種類別

• 化学療法
• 放射線治療
• 手術
• 治療用HPVワクチン

第8章 子宮頸部異形成市場：エンドユーザー別

• 外来手術センター
• 診断センター
• 病院
• 調査・学術機関
• 専門クリニック

第9章 南北アメリカの子宮頸部異形成市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の子宮頸部異形成市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの子宮頸部異形成市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Asieris Pharmaceuticals
• ASKA Pharmaceutical Co., Ltd.
• Becton, Dickinson, and Company
• BetterLife Pharma Inc.
• Bristol-Myers Squibb Company
• Cardinal Health Inc.
• CooperSurgical Inc
• DYSIS Medical Ltd.
• F. Hoffmann La-Roche Ltd
• GlaxoSmithKline PLC
• Guided Therapeutics, Inc.
• Helix BioPharma Corp.
• Hologic, Inc.
• Karl Kaps GmbH & Co. KG
• OncoHealth Corp
• PDS Biotechnology company
• Polaris Pharmaceuticals, Inc.
• Qiagen N.V.
• Quest Diagnostics, Inc.
• ViciniVax B.V.

LIST OF FIGURES

• FIGURE 1. CERVICAL DYSPLASIA MARKET RESEARCH PROCESS
• FIGURE 2. CERVICAL DYSPLASIA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CERVICAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CERVICAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CERVICAL DYSPLASIA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CERVICAL DYSPLASIA MARKET DYNAMICS
• TABLE 7. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY COLPOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY HPV TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY PAP SMEAR TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY THERAPEUTIC HPV VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CERVICAL DYSPLASIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CERVICAL DYSPLASIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CERVICAL DYSPLASIA MARKET SIZE, BY DIAGNOSTICS TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CERVICAL DYSPLASIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM CERVICAL DYSPLASIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. CERVICAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. CERVICAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023

The Cervical Dysplasia Market was valued at USD 754.39 million in 2023, expected to reach USD 806.03 million in 2024, and is projected to grow at a CAGR of 6.93%, to USD 1,206.52 million by 2030.

Cervical dysplasia, characterized by precancerous changes in cervical cells due to the Human Papillomavirus (HPV), demands significant attention in healthcare markets due to its role in cervical cancer prevention. Necessity arises from its potential to progress to cervical cancer if untreated, emphasizing the importance of screening programs like Pap smears and HPV testing. These applications, alongside vaccinations, form the backbone of preventive healthcare, significantly influencing market dynamics with end-users predominantly being hospitals, clinics, and diagnostic centers. The cervical dysplasia market is poised for growth driven by increased awareness, government initiatives for cervical cancer screening, and advancements in diagnostic technologies. Key growth influencers include the rising global HPV incidence and the growing emphasis on women's health, alongside the development of next-gen diagnostic tests. Geographically, emerging markets in Asia-Pacific and Latin America are robust growth zones due to healthcare infrastructure development and rising healthcare access. Nonetheless, challenges such as the high cost of diagnostic procedures, limited awareness in rural areas, and vaccine hesitancy continue to hinder market expansion. To navigate these, companies should focus on cost-effective diagnostic solutions and awareness programs. Innovation areas include developing non-invasive, accurate, and faster diagnostic methods; leveraging AI and machine learning for predictive diagnostics; and improving vaccine formulations for broader HPV protection. Engaging in partnerships for technology exchange and regional expansions could propel growth. The market is competitive with major players investing in R&D and strategic collaborations to enhance their portfolios. Companies aiming for robust business growth should prioritize cutting-edge research, deliver affordable healthcare solutions, and tap into untouched markets, while navigating regulatory landscapes and addressing socio-cultural barriers in low-awareness regions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cervical Dysplasia Market

The Cervical Dysplasia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of cervical cancer worldwide
  • Rising initiatives by the government to enhance the screening of cervical dysplasia
  • Inclination of patients towards minimal invasive surgeries
• Market Restraints
  • High cost of diagnostic devices and treatment
• Market Opportunities
  • Technological advancements in screening devices and other supporting equipment
  • Emergence of cervical screening programs
• Market Challenges
  • Lack of awareness in developing countries and low diagnostic device approval rate

Porter's Five Forces: A Strategic Tool for Navigating the Cervical Dysplasia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cervical Dysplasia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cervical Dysplasia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cervical Dysplasia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cervical Dysplasia Market

A detailed market share analysis in the Cervical Dysplasia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cervical Dysplasia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cervical Dysplasia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cervical Dysplasia Market

A strategic analysis of the Cervical Dysplasia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cervical Dysplasia Market, highlighting leading vendors and their innovative profiles. These include Asieris Pharmaceuticals, ASKA Pharmaceutical Co., Ltd., Becton, Dickinson, and Company, BetterLife Pharma Inc., Bristol-Myers Squibb Company, Cardinal Health Inc., CooperSurgical Inc, DYSIS Medical Ltd., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Guided Therapeutics, Inc., Helix BioPharma Corp., Hologic, Inc., Karl Kaps GmbH & Co. KG, OncoHealth Corp, PDS Biotechnology company, Polaris Pharmaceuticals, Inc., Qiagen N.V., Quest Diagnostics, Inc., and ViciniVax B.V..

Market Segmentation & Coverage

This research report categorizes the Cervical Dysplasia Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnostics Type, market is studied across Biopsy, Colposcopy, HPV Test, and Pap Smear Test.
• Based on Treatment Type, market is studied across Chemotherapy, Radiation Therapy, Surgery, and Therapeutic HPV Vaccines.
• Based on End-User, market is studied across Ambulatory Surgery Centers, Diagnostic Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of cervical cancer worldwide
    • 5.1.1.2. Rising initiatives by the government to enhance the screening of cervical dysplasia
    • 5.1.1.3. Inclination of patients towards minimal invasive surgeries
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diagnostic devices and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in screening devices and other supporting equipment
    • 5.1.3.2. Emergence of cervical screening programs
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness in developing countries and low diagnostic device approval rate
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cervical Dysplasia Market, by Diagnostics Type

• 6.1. Introduction
• 6.2. Biopsy
• 6.3. Colposcopy
• 6.4. HPV Test
• 6.5. Pap Smear Test

7. Cervical Dysplasia Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Radiation Therapy
• 7.4. Surgery
• 7.5. Therapeutic HPV Vaccines

8. Cervical Dysplasia Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgery Centers
• 8.3. Diagnostic Centers
• 8.4. Hospitals
• 8.5. Research & Academic Institutes
• 8.6. Specialty Clinics

9. Americas Cervical Dysplasia Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cervical Dysplasia Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cervical Dysplasia Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Asieris Pharmaceuticals
• 2. ASKA Pharmaceutical Co., Ltd.
• 3. Becton, Dickinson, and Company
• 4. BetterLife Pharma Inc.
• 5. Bristol-Myers Squibb Company
• 6. Cardinal Health Inc.
• 7. CooperSurgical Inc
• 8. DYSIS Medical Ltd.
• 9. F. Hoffmann La-Roche Ltd
• 10. GlaxoSmithKline PLC
• 11. Guided Therapeutics, Inc.
• 12. Helix BioPharma Corp.
• 13. Hologic, Inc.
• 14. Karl Kaps GmbH & Co. KG
• 15. OncoHealth Corp
• 16. PDS Biotechnology company
• 17. Polaris Pharmaceuticals, Inc.
• 18. Qiagen N.V.
• 19. Quest Diagnostics, Inc.
• 20. ViciniVax B.V.